0.168
前日終値:
$0.179
開ける:
$0.1951
24時間の取引高:
23.14M
Relative Volume:
1.96
時価総額:
$82.13M
収益:
$55.54M
当期純損益:
$-180.40M
株価収益率:
-0.2133
EPS:
-0.7877
ネットキャッシュフロー:
$-170.32M
1週間 パフォーマンス:
-5.30%
1か月 パフォーマンス:
-12.82%
6か月 パフォーマンス:
-95.10%
1年 パフォーマンス:
-86.98%
Gossamer Bio Inc Stock (GOSS) Company Profile
Compare GOSS vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
GOSS
Gossamer Bio Inc
|
0.168 | 82.13M | 55.54M | -180.40M | -170.32M | -0.7877 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-23 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2026-02-24 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2026-02-24 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2026-02-24 | ダウングレード | Wedbush | Outperform → Neutral |
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2025-09-10 | アップグレード | UBS | Neutral → Buy |
| 2025-07-14 | 開始されました | Scotiabank | Sector Outperform |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-04-05 | 再開されました | Wedbush | Outperform |
| 2023-07-27 | ダウングレード | UBS | Buy → Neutral |
| 2023-03-07 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | 開始されました | Guggenheim | Neutral |
| 2022-12-07 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2022-12-07 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-12-07 | ダウングレード | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | 開始されました | Goldman | Buy |
| 2022-09-21 | 開始されました | JP Morgan | Neutral |
| 2022-09-19 | 開始されました | Wedbush | Outperform |
| 2022-04-18 | 開始されました | Raymond James | Outperform |
| 2022-04-06 | 開始されました | UBS | Buy |
| 2022-01-10 | アップグレード | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-09-21 | 再開されました | Piper Sandler | Overweight |
| 2020-06-29 | 開始されました | H.C. Wainwright | Buy |
| 2020-04-22 | 開始されました | Piper Sandler | Overweight |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2019-12-03 | 再開されました | BofA/Merrill | Buy |
| 2019-10-30 | 開始されました | Berenberg | Buy |
| 2019-03-05 | 開始されました | Barclays | Overweight |
| 2019-03-05 | 開始されました | BofA/Merrill | Buy |
| 2019-03-05 | 開始されました | Evercore ISI | Outperform |
| 2019-03-05 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Gossamer Bio Inc (GOSS) 最新ニュース
Gossamer Bio (GOSS) Stock Faces Mixed Analyst Target Changes On Funding Risk - Yahoo Finance
Gossamer Bio Insiders Are Down US$45k But Regain Some Losses - simplywall.st
Gossamer Bio Inc (GOSS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Gossamer Bio Inc (GOSS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Gossamer Bio Inc (GOSS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Gossamer Bio Stock Plummeted 82% Today — What’s Behind The Crash? - Stocktwits
Gossamer Bio Inc (GOSS) Q1 2026 Earnings Call Highlights: Strategic Debt Reduction and ... By GuruFocus - Investing.com Canada
Gossamer Bio Inc (GOSS) Q1 2026 Earnings Call Highlights: Strate - GuruFocus
Gossamer Bio Inc. has officially announced the final tender results for its exchange offer and consent solicitation regarding its outstanding convertible notes. - Bitget
683 Capital Management, LLC Acquires Significant Stake in Gossamer Bio Inc - GuruFocus
Gossamer Bio Inc (GOSS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GOSS: Gossamer Bio Concludes Exchange Offer for Convertible Seni - GuruFocus
Gossamer Bio Inc (GOSS) Institutional Confidence - TradingKey
Gossamer Bio Inc (GOSS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Gossamer Bio completes exchange offer for convertible notes By Investing.com - Investing.com South Africa
Gossamer Bio completes exchange offer for convertible notes - Investing.com
Gossamer Bio Inc (GOSS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Gossamer Bio final tender results: $72M new notes, 317.6M shares available; $18.95M old notes remain - TradingView
Gossamer Bio (NASDAQ: GOSS) swaps most 2027 converts into 2030 debt and equity - Stock Titan
Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes - Business Wire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gossamer Bio, Inc. (GOSS) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Context Capital Management, LLC Acquires Significant Stake in Go - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Gossamer Bio, Inc. (GOSS) Investors to Inquire about Securities Investigation - ACCESS Newswire
D. E. Shaw (GOSS) discloses 9.5% stake after major exchange offer - Stock Titan
David E. Shaw Discloses Investment at Gossamer Bio with 9.5% Stake - TradingView
[SCHEDULE 13G] Gossamer Bio, Inc. Passive Investment Disclosure (>5%) - Stock Titan
683 Capital reports 49.87M-share position in Gossamer Bio (NASDAQ: GOSS) - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gossamer Bio, Inc. (GOSS) And Encourages Investors to Reach Out - ACCESS Newswire
2026-06-11 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gossamer Bio, Inc. (GOSS) And Encourages Investors to Reach Out | NDAQ:GOSS | Press Release - Stockhouse
Massive recapitalization at Gossamer Bio (NASDAQ: GOSS) could give noteholders majority control - Stock Titan
Context Capital (GOSS) discloses 48.8M-share, 9.9% stake in Gossamer Bio - Stock Titan
Gossamer Bio (NASDAQ: GOSS) awards 115K stock options to director - Stock Titan
Gossamer Bio (GOSS) director Skye Drynan awarded 115,000 stock options at $0.178 - Stock Titan
Gossamer Bio (GOSS) director receives 115,000 stock options as board compensation grant - Stock Titan
Director at Gossamer Bio (NASDAQ: GOSS) receives 115K stock options - Stock Titan
Gossamer Bio (GOSS) director awarded 115,000 stock options as compensation - Stock Titan
Gossamer Bio (NASDAQ: GOSS) awards director 115,000 stock options - Stock Titan
Gossamer Bio, Inc. 8-K Filing June 2026: Annual Meeting Results and Company Information - Minichart
Gossamer Bio, Inc. Announces Early Settlement and New Indenture for Senior Secured Convertible Notes Due 2030 - Minichart
Gossamer Bio (NASDAQ: GOSS) swaps $181M converts for new debt, equity and warrants - Stock Titan
Gossamer Bio (GOSS) holders re-elect directors and approve say-on-pay - Stock Titan
Gossamer Bio, Inc. Announces Early Tender Results and Early Settlement for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes - BioSpace
GOSS: Gossamer Bio Announces Early Tender Results for Exchange O - GuruFocus
Gossamer Bio receives 90.5% tender in debt exchange offer By Investing.com - Investing.com Nigeria
Gossamer Bio receives 90.5% tender in debt exchange offer - Investing.com
How The Investment Story For Gossamer Bio (GOSS) Is Quietly Shifting Without New Analyst Signals - Yahoo Finance
Gossamer Bio Extends Early Tender Deadline for Convertible Note Exchange Offer to June 9 - geneonline.com
GOSS: Gossamer Bio Extends Tender Date for Convertible Notes Exc - GuruFocus
Gossamer Bio, Inc. Extends Early Tender Date for Exchange Offer and Consent Solicitation for Convertible Notes - Minichart
Gossamer Bio, Inc. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes - Business Wire
Gossamer Bio extends early tender date for exchange offer; $181.05M tendered, New Notes up to $72M - TradingView
Gossamer Bio Inc (GOSS) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):